Use of third line antiretroviral therapy in Latin America
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2014 |
| Outros Autores: | , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/10446 |
Resumo: | NIAID, IeDEA |
| id |
CRUZ_0d527604e6383d74c70b99d450f40198 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/10446 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Cesar, CarinaShepherd, Bryan E.Jenkins, Cathy A.Ghidinelli, MassimoCastro, Jose LuisSantos, Valdiléa Gonçalves Veloso dosCortes, Claudia P.Padgett, DenisRamirez, Brenda CrabtreeGotuzzo, EduardoFink, ValeriaDuran, AdrianaSued, OmarMcGowan, Catherine C.Cahn, Pedro2015-05-21T15:59:34Z2015-05-21T15:59:34Z2014CESAR, Carina et al. Use of third line antiretroviral therapy in Latin America. Plos One, v. 9, n. 9, p. 1-8, Apr. 2014.1932-6203https://www.arca.fiocruz.br/handle/icict/1044610.1371/journal.pone.01068871932-6203NIAID, IeDEAFundación Huésped. Buenos Aires, Argentina.Vanderbilt University. Nashville, TN, USA.Vanderbilt University. Nashville, TN, USA.Pan American Health Organization. Washington, DC, USA.Pan American Health Organization. Washington, DC, USA.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST e AIDS. Rio de Janeiro, RJ, Brasil.Universidad de Chile. Santiago, Chile.Instituto Hondureño de Seguridad Social and Hospital Escuela. Tegucigalpa, HondurasInstituto Nacional de Ciencias Médicas y Nutrición. Mexico City, MC, Mexico.Instituto de Medicina Tropical Alexander Von Humboldt. Lima, Peru.Fundación Huésped. Buenos Aires, Argentina.Coordinación Sida, Ministerio de Salud de la Ciudad Autónoma de Buenos Aires. Buenos Aires, Argentina.Fundación Huésped. Buenos Aires, Argentina.Vanderbilt University. Nashville, TN, USA.Fundación Huésped. Buenos Aires, Argentina.Background: Access to highly active antiretroviral therapy (HAART) is expanding in Latin America. Many patients require second and third line therapy due to toxicity, tolerability, failure, or a combination of factors. The need for third line HAART, essential for program planning, is not known. Methods: Antiretroviral-naı¨ve patients $18 years who started first HAART after January 1, 2000 in Caribbean, Central and South America Network (CCASAnet) sites in Argentina, Brazil, Honduras, Mexico, and Peru were included. Clinical trials participants were excluded. Third line HAART was defined as use of darunavir, tipranavir, etravirine, enfuvirtide, maraviroc or raltegravir. Need for third line HAART was defined as virologic failure while on second line HAART. Results: Of 5853 HAART initiators followed for a median of 3.5 years, 310 (5.3%) failed a second line regimen and 44 (0.8%) received a third line regimen. Cumulative incidence of failing a 2nd or starting a 3rd line regimen was 2.7% and 6.0% three and five years after HAART initiation, respectively. Predictors at HAART initiation for failing a second or starting a third line included female sex (hazard ratio [HR] = 1.54, 95% confidence interval [CI] 1.18–2.00, p = 0.001), younger age (HR = 2.76 for 20 vs. 40 years, 95% CI 1.86–4.10, p,0.001), and prior AIDS (HR = 2.17, 95% CI 1.62–2.90, p,0.001). Conclusions: Third line regimens may be needed for at least 6% of patients in Latin America within 5 years of starting HAART, a substantial proportion given the large numbers of patients on HAART in the region. Improved accessibility to third line regimens is warranted.engPublic Library of ScienceUse of third line antiretroviral therapy in Latin Americainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleHighly active antiretroviral therapy,Latin AmericaHIVProtease inhibitorsTerapia antirretroviral de alta atividadeAmérica LatinaHIVInibidores de proteasesinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82352https://www.arca.fiocruz.br/bitstream/icict/10446/1/license.txtafbdf7d7a9bcf771a1cc7edf5f618413MD51ORIGINALUse of Third Line Antiretroviral Therapy in Latin America.pdfUse of Third Line Antiretroviral Therapy in Latin America.pdfapplication/pdf221097https://www.arca.fiocruz.br/bitstream/icict/10446/2/Use%20of%20Third%20Line%20Antiretroviral%20Therapy%20in%20Latin%20America.pdf7e4d205730a0bfd79d7ad6006baee3e8MD52TEXTUse of Third Line Antiretroviral Therapy in Latin America.pdf.txtUse of Third Line Antiretroviral Therapy in Latin America.pdf.txtExtracted texttext/plain38726https://www.arca.fiocruz.br/bitstream/icict/10446/3/Use%20of%20Third%20Line%20Antiretroviral%20Therapy%20in%20Latin%20America.pdf.txt5af0a7bed5d64cb5cf01de8ebb4e5b0bMD53icict/104462019-09-10 10:55:33.749oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352019-09-10T13:55:33Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Use of third line antiretroviral therapy in Latin America |
| title |
Use of third line antiretroviral therapy in Latin America |
| spellingShingle |
Use of third line antiretroviral therapy in Latin America Cesar, Carina Highly active antiretroviral therapy, Latin America HIV Protease inhibitors Terapia antirretroviral de alta atividade América Latina HIV Inibidores de proteases |
| title_short |
Use of third line antiretroviral therapy in Latin America |
| title_full |
Use of third line antiretroviral therapy in Latin America |
| title_fullStr |
Use of third line antiretroviral therapy in Latin America |
| title_full_unstemmed |
Use of third line antiretroviral therapy in Latin America |
| title_sort |
Use of third line antiretroviral therapy in Latin America |
| author |
Cesar, Carina |
| author_facet |
Cesar, Carina Shepherd, Bryan E. Jenkins, Cathy A. Ghidinelli, Massimo Castro, Jose Luis Santos, Valdiléa Gonçalves Veloso dos Cortes, Claudia P. Padgett, Denis Ramirez, Brenda Crabtree Gotuzzo, Eduardo Fink, Valeria Duran, Adriana Sued, Omar McGowan, Catherine C. Cahn, Pedro |
| author_role |
author |
| author2 |
Shepherd, Bryan E. Jenkins, Cathy A. Ghidinelli, Massimo Castro, Jose Luis Santos, Valdiléa Gonçalves Veloso dos Cortes, Claudia P. Padgett, Denis Ramirez, Brenda Crabtree Gotuzzo, Eduardo Fink, Valeria Duran, Adriana Sued, Omar McGowan, Catherine C. Cahn, Pedro |
| author2_role |
author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Cesar, Carina Shepherd, Bryan E. Jenkins, Cathy A. Ghidinelli, Massimo Castro, Jose Luis Santos, Valdiléa Gonçalves Veloso dos Cortes, Claudia P. Padgett, Denis Ramirez, Brenda Crabtree Gotuzzo, Eduardo Fink, Valeria Duran, Adriana Sued, Omar McGowan, Catherine C. Cahn, Pedro |
| dc.subject.en.pt_BR.fl_str_mv |
Highly active antiretroviral therapy, Latin America HIV Protease inhibitors |
| topic |
Highly active antiretroviral therapy, Latin America HIV Protease inhibitors Terapia antirretroviral de alta atividade América Latina HIV Inibidores de proteases |
| dc.subject.decs.pt_BR.fl_str_mv |
Terapia antirretroviral de alta atividade América Latina HIV Inibidores de proteases |
| description |
NIAID, IeDEA |
| publishDate |
2014 |
| dc.date.issued.fl_str_mv |
2014 |
| dc.date.accessioned.fl_str_mv |
2015-05-21T15:59:34Z |
| dc.date.available.fl_str_mv |
2015-05-21T15:59:34Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
CESAR, Carina et al. Use of third line antiretroviral therapy in Latin America. Plos One, v. 9, n. 9, p. 1-8, Apr. 2014. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/10446 |
| dc.identifier.issn.none.fl_str_mv |
1932-6203 |
| dc.identifier.doi.none.fl_str_mv |
10.1371/journal.pone.0106887 |
| dc.identifier.eissn.none.fl_str_mv |
1932-6203 |
| identifier_str_mv |
CESAR, Carina et al. Use of third line antiretroviral therapy in Latin America. Plos One, v. 9, n. 9, p. 1-8, Apr. 2014. 1932-6203 10.1371/journal.pone.0106887 |
| url |
https://www.arca.fiocruz.br/handle/icict/10446 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Public Library of Science |
| publisher.none.fl_str_mv |
Public Library of Science |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/10446/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/10446/2/Use%20of%20Third%20Line%20Antiretroviral%20Therapy%20in%20Latin%20America.pdf https://www.arca.fiocruz.br/bitstream/icict/10446/3/Use%20of%20Third%20Line%20Antiretroviral%20Therapy%20in%20Latin%20America.pdf.txt |
| bitstream.checksum.fl_str_mv |
afbdf7d7a9bcf771a1cc7edf5f618413 7e4d205730a0bfd79d7ad6006baee3e8 5af0a7bed5d64cb5cf01de8ebb4e5b0b |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009049571033088 |